Latest Commercial Rollout News

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Proteomics International Laboratories has achieved ISO 15189 certification for its Australian lab, marking a pivotal step in commercialising its precision diagnostic tests like PromarkerD and PromarkerEso.

Memphasys has upgraded its contract with ITL to A$390,000 and expanded its territory to include Turkey, marking its first contracted revenues in the EU ahead of expected CE Mark approval.

Iondrive Limited has inked a binding Term Sheet with Livium Limited to commercialise its innovative Deep Eutectic Solvent (DES) technology for recycling critical materials from batteries, solar panels, and e-waste in Australia, with a pilot plant set to begin commissioning by the end of 2025.

EBR Systems has achieved a significant commercial milestone with its tenth US implant of the WiSE wireless cardiac pacing system, setting the stage for broader market adoption supported by new reimbursement schemes.

Locksley Resources has taken a significant step toward securing diversified antimony supply for the U.S. market by entering a non-binding agreement with EV Resources, supporting its proprietary DeepSolv™ processing technology and domestic critical minerals strategy.

Artrya Limited has raised A$75 million through a two-tranche placement and launched a A$5 million share purchase plan to fast-track the U.S. commercialisation of its AI-powered Salix platform following FDA clearance.

Proteomics International Laboratories announces the planned retirement of its founder and Managing Director, Dr Richard Lipscombe, in February 2026, marking a pivotal leadership transition as the company seeks a new CEO to drive its next growth phase.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

Compumedics has secured FDA clearance for its single-use Somfit®D device, effectively doubling its addressable U.S. home sleep testing market to an estimated US$240 million annually. This milestone positions the company to capture significant market share with a dual-platform EEG-based solution.

Green360 Technologies announces CEO Bojan Bogunovic's resignation effective October 31, with Executive Chairman Aaron Banks stepping in to lead daily operations during a pivotal growth phase.